ImmunityBio (IBRX) Treasury Shares (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Treasury Shares data on file, last reported at $5.9 million in Q1 2026.

• Treasury Shares for Q1 2026 came in at $5.9 million, up 3527.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.9 million (up 3527.36% YoY), and the FY2025 annual result was $163800.0, down 97.24% from the prior year.
• Treasury Shares climbed to $5.9 million in Q1 2026 per IBRX's latest filing, from $163800.0 in the prior quarter.
• Over five years, Treasury Shares peaked at $9.1 million in Q2 2025 and troughed at $163800.0 in Q2 2022.
• A 5-year average of $3.9 million and a median of $5.9 million in 2024 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2022 and 2024: Treasury Shares plunged 97.8% in 2022, then surged 3904.54% in 2024.
• A 5-year view of Treasury Shares shows it stood at $163800.0 in 2022, then changed by 0.0% to $163800.0 in 2023, then soared by 3529.68% to $5.9 million in 2024, then plunged by 97.24% to $163800.0 in 2025, then surged by 3527.36% to $5.9 million in 2026.
• Business Quant data shows IBRX's Treasury Shares at $5.9 million in Q1 2026, $163800.0 in Q4 2025, and $163800.0 in Q3 2025.